Results 151 to 160 of about 4,828 (174)

Palivizumab

2013
openaire   +1 more source

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

Current Medical Research and Opinion, 2008
Krista L Lanctôt, Bosco A Paes
exaly  

To Palivizumab or not to Palivizumab – that is the question

Paediatric Respiratory Reviews, 2013
openaire   +2 more sources

Palivizumab and RSVIG

Inpharma Weekly, 1998
openaire   +2 more sources

Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients

Journal of Infectious Diseases, 2018
Xunyan Ye, Vasanthi Avadhanula, Kirtida D Patel   +2 more
exaly  

Palivizumab

Drugs, 2012
exaly  

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

Pediatrics, 2014
Carrie L Byington, Anne M Gadomski, Eneida A Mendonca   +2 more
exaly  

Palivizumab

2016
openaire   +1 more source

Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV

Pediatrics, 1998
exaly  

Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience

Journal of Pediatrics, 2017
Octavio Ramilo, Asuncion Mejias, Pablo J Sánchez   +2 more
exaly